nature portfolio

Corresponding author(s):	Yan Li
Last updated by author(s):	2023-08-25
Last apaated by author(s).	2020 00 20

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

	ISTI	

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed				
	$\overrightarrow{}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	$\boxed{1}$ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
$\sqrt{}$	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
$\sqrt{}$	A description of all covariates tested				
$\sqrt{}$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
$\sqrt{}$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
$\sqrt{}$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\sqrt{}$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$\sqrt{}$	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
So	ftware and code				
Poli	cy information about <u>availability of computer code</u>				
Da	ata collection N.A.				
Da	All data were exported by GraphPad Prism 8.				
	nanuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and wers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Da	ta				
All	cy information about <u>availability of data</u> manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>				
N.	A.				

olicy information about stud <u>nd sexual orientation</u> and <u>ra</u>	es with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> e, ethnicity and racism.
Reporting on sex and gende	N.A.
Reporting on race, ethnicity other socially relevant groupings	or N.A.
Population characteristics	N.A.
Recruitment	N.A.
Ethics oversight	N.A.
te that full information on the	pproval of the study protocol must also be provided in the manuscript.
· · · · · · · · · · · · · · · · · · ·	
Life sciences	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences
Life sciences a reference copy of the document	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences
Life sciences a reference copy of the document fe sciences studies must disclose on the	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences
Life sciences a reference copy of the document fe sciences studies must disclose on the sample size	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences
Life sciences a reference copy of the document Compared to the sciences by the sciences compared to the document compared to the sciences studies must disclose on the sample size No calculation No data were	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences
Life sciences Life sciences The areference copy of the document Sample size Data exclusions Replication Randomization Colonies we performance	at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences

All studies must disclose on these points even when the disclosure is negative.

Study description	N.A.
Research sample	N.A.
Sampling strategy	N.A.
Data collection	N.A.
Timing	N.A.
Data exclusions	N.A.
Non-participation	N.A.
Randomization	N.A.

Study description Research sample N.A. Sampling strategy N.A. Data collection Timing and spatial scale Data exclusions Reproducibility N.A. Randomization Blinding N.A. Did the study involve field work? Field work, collection and	Yes No transport
Sampling strategy Data collection N.A. Timing and spatial scale N.A. Data exclusions N.A. Reproducibility N.A. Randomization N.A. Blinding N.A. Did the study involve field work?	
Data collection N.A. Timing and spatial scale N.A. Data exclusions N.A. Reproducibility N.A. Randomization N.A. Blinding N.A. Did the study involve field work?	
Timing and spatial scale N.A. Data exclusions N.A. Reproducibility N.A. Randomization N.A. Blinding N.A. Did the study involve field work?	
Data exclusions Reproducibility N.A. Randomization N.A. Blinding N.A. Did the study involve field work?	
Reproducibility N.A. Randomization N.A. Blinding N.A. Did the study involve field work?	
Randomization N.A. Blinding N.A. Did the study involve field work?	
Blinding N.A. Did the study involve field work?	
Did the study involve field work?	
Field conditions N.A. Location N.A.	
Access & import/export N.A.	
Disturbance N.A.	
We require information from authors about s system or method listed is relevant to your st Materials & experimental system n/a Involved in the study	cific materials, systems and methods some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, tudy. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods Na Involved in the study ChIP-seq
Antibodies Value Antibodies Antibodie	V ChIP-seq √
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms Clinical data	
Clinical data Dual use research of concern	

Antibodies

Antibodies used	anti-His antibody (TransGen Biotech Ltd, Beijing, China)
Validation	western blot

Eukaryotic cell lin	es		
Policy information about <u>ce</u>	ell lines	and Sex and Gender in Research	
Cell line source(s)		N.A.	
Authentication		N.A.	
Mycoplasma contamination		N.A.	
Commonly misidentified lines (See ICLAC register)		N.A.	
Palaeontology an	d Arc	haeology	
Specimen provenance	N.A		
Specimen deposition	N.A		
Dating methods	N.A		
Tick this box to confir	m that t	he raw and calibrated dates are available in the paper or in Supplementary Information.	
Ethics oversight	N.A.		
Note that full information on t	he appro	oval of the study protocol must also be provided in the manuscript.	
		earch organisms volving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in	
Research			
Laboratory animals	N.A.		
Wild animals	N.A.		
Reporting on sex	N.A.		
Field-collected samples	N.A.		
Ethics oversight	s oversight N.A.		
Note that full information on t	he appro	oval of the study protocol must also be provided in the manuscript.	
Clinical data			
Policy information about <u>cli</u> All manuscripts should comply		udies ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.	
Clinical trial registration	N.A.		
Study protocol	N.A.		
Data collection	N.A.		
Outcomes	N.A.		

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes			
Public health			
Crops and/or livestock			
. 1			
Any other significar	nt area		
Experiments of concern			
Does the work involve any of these experiments of concern:			
No Yes			
Demonstrate how to render a vaccine ineffective			
		eutically useful antibiotics or antiviral agents	
Enhance the virule		pathogen or render a nonpathogen virulent	
Alter the host range			
-, -		s/detection modalities	
		f a biological agent or toxin	
Any other potentia	lly harmf	ul combination of experiments and agents	
Plants	<u> </u>		
Seed stocks N.A.			
Novel plant genotypes N.A			
Authentication N.A			
ChIP-seq			
Data deposition			
Confirm that both raw	and fin	al processed data have been deposited in a public database such as <u>GEO</u> .	
Confirm that you have	e deposit	ted or provided access to graph files (e.g. BED files) for the called peaks.	
Data access links May remain private before public	cation.	N.A.	
Files in database submissi	ion	N.A.	
Genome browser session (e.g. <u>UCSC</u>)		N.A.	
Methodology			
Replicates N.A.			
Sequencing depth	N.A.		
Antibodies	N.A.		
Peak calling parameters	N.A.		
Data quality	N.A.		
Software N.A.			

Flow Cytometry	
Plots Confirm that: The axis labels state the ma	arker and fluorochrome used (e.g. CD4-FITC). visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots v	with outliers or pseudocolor plots.
A numerical value for numb	ber of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	N.A.
Instrument	N.A.
Software	N.A.
Cell population abundance	N.A.
Gating strategy	N.A.
Tick this box to confirm tha	at a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance Experimental design	imaging
Design type	N.A.
Design specifications	N.A.
Behavioral performance measu	ures N.A.
Imaging type(s)	N.A.
Field strength	N.A.
Sequence & imaging paramete	ers N.A.
Area of acquisition	N.A.
Diffusion MRI Used	Not used
Preprocessing	
Preprocessing software	N.A.
Normalization	N.A.
Normalization template	N.A.
Noise and artifact removal	N.A.
Volume censoring	N.A.
Statistical modeling & infer	rence
Model type and settings	N.A.

Model type and settings	N.A.				
Effect(s) tested	(N.A.				
Specify type of analysis: W	/hole brain ROI-based Both				

nature portfolio
reporting summa

S	
Ī	
C	\sim
	2
	~

Statistic type for inference	I.A.	
(See Eklund et al. 2016)		
Correction	N.A.	
Models & analysis		
n/a Involved in the study Functional and/or effective of Graph analysis Multivariate modeling or predictions	ŕ	
Functional and/or effective connec	tivity N.A.	
Graph analysis	N.A.	
Multivariate modeling and predicti	ve analysis N.A.	